(Q35674179)

9 August 2017

1 reference

title

Review of antibiotic resistance, antibiotic treatment and prevention of pneumococcal pneumonia (English)

1 reference

9 August 2017

main subject

antibiotic resistance

1 reference

Sheldon L Kaplan

1

1 reference

9 August 2017

publication date

1 January 2004

1 reference

Paediatric Respiratory Reviews

9 August 2017

published in

1 reference

9 August 2017

volume

5 Suppl A

1 reference

9 August 2017

page(s)

S153-8

1 reference

Pneumococcal resistance to antibiotics

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990030-9

7 January 2021

Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990030-9

7 January 2021

Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999--2000, including a comparison of resistance rates since 1994--1995.

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990030-9

7 January 2021

Six year multicenter surveillance of invasive pneumococcal infections in children

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990030-9

7 January 2021

Macrolide resistance among invasive Streptococcus pneumoniae isolates

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990030-9

7 January 2021

Molecular surveillance of macrolide, tetracycline and quinolone resistance mechanisms in 1191 clinical European Streptococcus pneumoniae isolates

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990030-9

7 January 2021

Mutations in the dihydrofolate reductase gene of trimethoprim-resistant isolates of Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990030-9

7 January 2021

Emerging mechanisms of fluoroquinolone resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990030-9

7 January 2021

Management of infections due to antibiotic-resistant Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990030-9

7 January 2021

Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990030-9

7 January 2021

Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990030-9

7 January 2021

Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990030-9

7 January 2021

Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990030-9

7 January 2021

Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae. The Streptococcus pneumoniae Working Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990030-9

7 January 2021

Clinical outcome of invasive infections by penicillin-resistant Streptococcus pneumoniae in Korean children

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990030-9

7 January 2021

Clinical characteristics and outcome of children with pneumonia attributable to penicillin-susceptible and penicillin-nonsusceptible Streptococcus pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990030-9

7 January 2021

Complicated parapneumonic effusions in children caused by penicillin-nonsusceptible Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990030-9

7 January 2021

Outcome of invasive infections outside the central nervous system caused by Streptococcus pneumoniae isolates nonsusceptible to ceftriazone in children treated with beta-lactam antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990030-9

7 January 2021

Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978-1997.

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990030-9

7 January 2021

Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990030-9

7 January 2021

Breakthrough bacteremia and meningitis during treatment with cephalosporins parenterally for pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990030-9

7 January 2021

Pneumococcal meningitis during therapy of otitis media with clarithromycin.

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990030-9

7 January 2021

Breakthrough sepsis in macrolide-resistant pneumococcal infection

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990030-9

7 January 2021

Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990030-9

7 January 2021

Breakthrough Streptococcus pneumoniae meningitis during clarithromycin therapy for acute otitis media.

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990030-9

7 January 2021

Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Linezolid Pediatric Pneumonia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990030-9

7 January 2021

Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990030-9

7 January 2021

Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990030-9

7 January 2021

Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants.

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990030-9

7 January 2021

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990030-9

7 January 2021

Policy Statement: Recommendations for the Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate Vaccine (Prevnar), Pneumococcal Polysaccharide Vaccine, and Antibiotic Prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990030-9

7 January 2021

Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990030-9

7 January 2021

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990030-9

7 January 2021

10.1016/S1526-0542(04)90030-9

Identifiers

DOI

1 reference

9 August 2017

1 reference